#London #United Kingdom #Clinical Trials #Image Analysis Group #DYNAMIKA

The imaging landscape in clinical trials has taken a significant leap forward with the introduction of DYNAMIKA V.7 by the Image Analysis Group (IAG), a prominent imaging Clinical Research Organization (iCRO). This advanced cloud-based platform is specifically designed for the management and analysis of imaging data in clinical trials, showcasing IAG's ongoing commitment to innovation in medical imaging. This recent iteration, DYNAMIKA V.7, not only enhances operational efficiency but has also successfully obtained the British Standards Institute (BSI) surveillance audit certification, joining the ranks of certified platforms post a recent SOC II Type I compliance certification.

DYNAMIKA has been recognized as an Award Category Winner for Innovation at the 2024 Pharmaceutical Technology Excellence Awards, highlighting its proprietary technology that promises to transform the pharmaceutical industry. Dr. Olga Kubassova, the founder and President of IAG, emphasized the significance of this milestone, stating, "This milestone is another important step as IAG continues to bring innovation to the medical imaging space." The innovative capabilities of DYNAMIKA enable IAG to forge partnerships with companies looking for effective imaging biomarkers that are critical for assessing the safety and efficacy of their drug candidates during clinical trials. It's also poised to serve as a companion diagnostic tool in clinical settings.

At the heart of DYNAMIKA is its ability to streamline medical imaging workflows, which is essential for data management and quality control. The platform provides a central review system for clinical imaging, making it easier for investigators to evaluate treatment efficacy and safety. Here are some standout features of DYNAMIKA V.7:

• - User-Friendly Interface: DYNAMIKA simplifies and automates imaging workflows, allowing users to navigate the platform with ease.
• - Accelerated Reading Process: The platform expedites the radiological reading process, minimizing the burden on sites and enhancing collaboration and participation.
• - Consistency in Imaging Assessments: It promotes greater uniformity in radiological reads, which ultimately improves the accuracy and reliability of imaging assessments.
• - Data Interoperability: DYNAMIKA aggregates information to furnish operational leaders with comprehensive, real-time insights, enabling informed decision-making.
• - Broad Support for Trials: The platform is designed to support Phase I to IV trials of any scale, which means it is equipped to handle the diverse requirements of varying clinical studies.

IAG's commitment to quality is further underscored by DYNAMIKA’s development in accordance with 21CFR Part 11 regulations—established by the United States Food and Drug Administration (FDA)—and compliance with ISO 13485, a recognized standard for quality management systems in the medical device industry. These certifications reaffirm IAG's dedication to maintaining the highest standards in quality and security while pushing the frontiers of innovation in clinical research.

Since its establishment in 2007, the Image Analysis Group has been at the forefront of imaging solutions for biotech and pharmaceutical clients around the world. IAG’s pioneering approach, backed by proven capabilities, is instrumental in enhancing the value and market potential of novel therapeutic assets. Through strategic collaborations with pharmaceutical companies, IAG has successfully contributed to various phases of imaging trials spanning multiple indications.

For those looking to elevate their clinical trial imaging processes, DYNAMIKA V.7 emerges as a game-changing solution that leverages state-of-the-art technology to deliver comprehensive insights and enhance operational efficiencies across the board. To learn more about IAG and DYNAMIKA, potential partners and clients can connect with their representatives directly.